JP2018083843A5 - - Google Patents

Download PDF

Info

Publication number
JP2018083843A5
JP2018083843A5 JP2018012496A JP2018012496A JP2018083843A5 JP 2018083843 A5 JP2018083843 A5 JP 2018083843A5 JP 2018012496 A JP2018012496 A JP 2018012496A JP 2018012496 A JP2018012496 A JP 2018012496A JP 2018083843 A5 JP2018083843 A5 JP 2018083843A5
Authority
JP
Japan
Prior art keywords
demethyl
pharmaceutical composition
deoxo
compared
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018012496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018083843A (ja
JP6851334B2 (ja
Filing date
Publication date
Priority claimed from KR1020140099210A external-priority patent/KR101694879B1/ko
Application filed filed Critical
Publication of JP2018083843A publication Critical patent/JP2018083843A/ja
Publication of JP2018083843A5 publication Critical patent/JP2018083843A5/ja
Application granted granted Critical
Publication of JP6851334B2 publication Critical patent/JP6851334B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018012496A 2014-08-01 2018-01-29 免疫抑制活性なしに神経再生活性が維持されるfk506誘導体及びその用途 Active JP6851334B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0099210 2014-08-01
KR1020140099210A KR101694879B1 (ko) 2014-08-01 2014-08-01 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017526030A Division JP6370490B2 (ja) 2014-08-01 2015-07-31 免疫抑制活性なしに神経再生活性が維持されるfk506誘導体及びその用途

Publications (3)

Publication Number Publication Date
JP2018083843A JP2018083843A (ja) 2018-05-31
JP2018083843A5 true JP2018083843A5 (https=) 2018-07-26
JP6851334B2 JP6851334B2 (ja) 2021-03-31

Family

ID=55217893

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526030A Active JP6370490B2 (ja) 2014-08-01 2015-07-31 免疫抑制活性なしに神経再生活性が維持されるfk506誘導体及びその用途
JP2018012496A Active JP6851334B2 (ja) 2014-08-01 2018-01-29 免疫抑制活性なしに神経再生活性が維持されるfk506誘導体及びその用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017526030A Active JP6370490B2 (ja) 2014-08-01 2015-07-31 免疫抑制活性なしに神経再生活性が維持されるfk506誘導体及びその用途

Country Status (6)

Country Link
US (2) US10226446B2 (https=)
EP (1) EP3187183B1 (https=)
JP (2) JP6370490B2 (https=)
KR (1) KR101694879B1 (https=)
CN (2) CN106794169B (https=)
WO (1) WO2016018117A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
CN113939519B (zh) * 2018-12-11 2025-02-14 莫尔根生物有限公司 促进毛发生长的新化合物及包含它们的组合物
US11449807B2 (en) 2020-01-31 2022-09-20 Walmart Apollo, Llc Systems and methods for bootstrapped machine learning algorithm training
WO2021256894A1 (ko) * 2020-06-19 2021-12-23 서울대학교 산학협력단 신경 돌기 생장 및 시냅스 형성 활성을 갖는 신규 prolylfk506 유도체 및 그의 용도
CN118460433B (zh) * 2024-06-04 2026-01-06 浙江启臻合成生物技术有限公司 生产他克莫司的链霉菌工程菌及其构建方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
EP1595541A1 (en) * 2004-05-12 2005-11-16 Alcasynn Pharmaceuticals Gmbh Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
CA2673863A1 (en) 2006-12-28 2008-07-10 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
WO2009158031A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
KR101261131B1 (ko) 2010-08-24 2013-05-06 이화여자대학교 산학협력단 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
KR101632042B1 (ko) * 2014-06-30 2016-06-21 주식회사 인트론바이오테크놀로지 Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2018083843A5 (https=)
EP4596041A3 (en) Farnesoid x receptor agonists and uses thereof
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
JP2016518337A5 (https=)
EP4011871A3 (en) Processes for preparing oxathiazin-like compounds
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
WO2017035353A8 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
JP2016147915A5 (https=)
EP3973586A4 (en) NEW PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL, BEHAVIORAL AND COGNITIVE DISORDERS
JP2020536085A5 (https=)
EP4434966A4 (en) PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR CYTOLOGICALLY ACCEPTABLE SALT THEREOF AND COMPOSITION FOR THE PREVENTION, RELIEF OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING IT AS AN ACTIVE INGREDIENT
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
JP2018508329A5 (https=)
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
WO2017070689A3 (en) Solabegron zwitterion and uses thereof
EP4008718C0 (en) HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE
FI3248597T3 (fi) Terapeuttinen aine sensorineuraaliseen kuulonmenetykseen
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
JP2019505549A5 (https=)
IL273929B1 (en) Therapeutic agents for neurodegenerative diseases
EA201991817A1 (ru) Интраназальная композиция, включающая бетагистин